0001437749-22-028439.txt : 20221205 0001437749-22-028439.hdr.sgml : 20221205 20221205173012 ACCESSION NUMBER: 0001437749-22-028439 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221121 FILED AS OF DATE: 20221205 DATE AS OF CHANGE: 20221205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kunin Audrey CENTRAL INDEX KEY: 0001738781 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33678 FILM NUMBER: 221445959 MAIL ADDRESS: STREET 1: 4346 BELGIUM BLVD NW CITY: RIVERSIDE STATE: MO ZIP: 64150 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBay Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001389545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680454536 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 899-8800 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 4/A 1 rdgdoc.xml FORM 4 X0306 4/A 2022-11-21 2022-11-23 0001389545 NovaBay Pharmaceuticals, Inc. NBY 0001738781 Kunin Audrey C/O NOVABAY PHARMACEUTICALS, INC. 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 1 Chief Product Officer Common Stock 2022-11-21 4 S 0 5960 2.10490 D 1 I See footnote On November 15, 2022, the common stock of NovaBay Pharmaceuticals, Inc. split 1-for-35, and is reflected accordingly in the number of shares sold. This transaction was executed in multiple trades at prices ranging from $2.09 to $2.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The original Form 4, filed on November 23, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported that the reporting person beneficially owned no shares following the reported transaction when in fact the reporting person beneficially owned one share following the reported transaction. By The Audrey G. Kunin Trust in which the reporting person serves as the trustee and has investment control. /s/ Audrey Kunin 2022-12-05